论文部分内容阅读
目的:观察灯盏细辛注射液对重症颅脑损伤患者疗效及神经功能恢复的影响。方法:选取2014年1月~2016年3月期间收治的行手术治疗的重症颅脑损伤患者72例为研究资料,随机抽取36例为对照组,并采用降颅压、抗炎、等对症支持治疗,观察组(36例)在对照组基础上加用灯盏细辛注射液治疗。对比分析两组相关指标水平。结果:治疗后3个月,观察组GCS和NIHSS评分分别为(10.41±0.47、12.51±1.06)分,均明显优于对照组(8.73±0.39、19.04±1.35)分。治疗后4周,观察组血清肿瘤坏死因子-ɑ(TNF-ɑ)、降钙素基因相关肽(CGRP)和S100B蛋白水平分别为(1.89±0.37ng/L、40.04±0.93ng/L、0.34±0.11μg/L),均明显优于对照组(2.40±0.39ng/L、34.19±0.72ng/L、0.57±0.17μg/L)。治疗后4周,观察组血浆D-D和PT值分别为(0.35±0.07mg/L、13.25±0.48s),均明显优于对照组(0.49±0.08mg/L、15.95±0.51s)。(4)治疗后三个月,观察组预后评级为IV+V者的比例为47.22%,明显高于对照组22.22%。(5)治疗期间,两组患者均未发生明显的不良反应。结论:灯盏细辛注射液可调节重症颅脑损伤患者相关因子水平、促进患者神经功能恢复,从而改善患者预后。
Objective: To observe the effect of Erigeron Breviscapus Injection on the curative effect and nerve function recovery of patients with severe craniocerebral injury. Methods: Seventy-two patients with severe craniocerebral injury underwent surgical treatment from January 2014 to March 2016 were selected as study data, 36 patients were randomly selected as the control group, and intracranial pressure, anti-inflammatory and symptomatic supportive Treatment, observation group (36 cases) on the basis of the control group with Erigeron Injection treatment. Comparative analysis of the two groups related indicators. Results: The scores of GCS and NIHSS in the observation group were (10.41 ± 0.47, 12.51 ± 1.06) points at 3 months after treatment, which were significantly better than those in the control group (8.73 ± 0.39 and 19.04 ± 1.35). At 4 weeks after treatment, the levels of tumor necrosis factor-α (TNF-ɑ), calcitonin gene related peptide (CGRP) and S100B in observation group were (1.89 ± 0.37ng / L, 40.04 ± 0.93ng / L, ± 0.11μg / L) were significantly better than the control group (2.40 ± 0.39ng / L, 34.19 ± 0.72ng / L, 0.57 ± 0.17μg / L). At 4 weeks after treatment, the plasma D-D and PT values in the observation group were (0.35 ± 0.07mg / L, 13.25 ± 0.48s), respectively, which were significantly better than those in the control group (0.49 ± 0.08mg / L, 15.95 ± 0.51s). (4) Three months after treatment, the proportion of observer group with prognosis of IV + V was 47.22%, which was significantly higher than that of the control group (22.22%). (5) During the treatment, no obvious adverse reactions occurred in both groups. Conclusion: Erigeron breviscapus injection can regulate the level of related factors in patients with severe craniocerebral injury, and promote the recovery of neurological function in patients, so as to improve the prognosis of patients.